Abstract:Abstract Background and Aims Lymphocyte activation gene [LAG]-3 is an immune checkpoint and its expression identifies recently activated lymphocytes that may contribute to inflammation. We investigated the role of LAG-3 by analysing its expression and function in immune cells from blood and tissue of patients with ulcerative colitis [UC]. Methods The phenotypic properties of LAG-3+ T cells were determined by flow cytometry, qRT-PCR and single-cell RNA-sequencing. LAG-3+ cells were quantified and correlated with disease activity. The functional effects of LAG-3+ cells were tested using a depleting anti-LAG-3 monoclonal antibody [mAb] in a mixed lymphocyte reaction [MLR]. Results LAG-3+ cells in the blood were negligible. LAG-3+ lymphocytes were markedly increased in inflamed mucosal tissue and both frequencies of LAG-3+ T cells and transcript levels of LAG3 correlated with endoscopic severity. LAG-3 expression was predominantly on effector memory T cells, and single-cell RNA-sequencing revealed LAG3 expression in activated and cytokine-producing T cell subsets. Foxp3+CD25hi Tregs also expressed LAG-3, although most mucosal Tregs were LAG-3−. Mucosal LAG-3+ cells produced mainly interferon γ [IFNγ] and interleukin-17A. LAG-3+ cell numbers decreased in patients who responded to biologics, and remained elevated in non-responders. Treatment with a depleting anti-LAG-3 mAb led to a reduction in proliferation and IFNγ production in an MLR. Conclusions LAG-3+ cells are increased in the inflamed mucosa, predominantly on effector memory T cells with an activated phenotype and their cell numbers positively correlate with disease activity. Depleting LAG-3 eliminates activated proliferating T cells, and hence LAG-3 could be a therapeutic target in UC.

CD3/TCR Complex-Associated Lymphocyte Activation Gene-3 Molecules Inhibit CD3/TCR Signaling

LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif

Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity

Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade

Understanding LAG-3 Signaling

The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy

Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II

Overexpression of Lymphocyte Activation Gene-3 Inhibits Regulatory T Cell Responses in Osteoarthritis.

Function and regulation of LAG3 on CD4(+)CD25(-) T cells in non-small cell lung cancer.

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis

LAG3 (CD223) and Autoimmunity: Emerging Evidence.

A Lysosomal Protein Negatively Regulates Surface T Cell Antigen Receptor Expression by Promoting Cd3 Zeta-Chain Degradation

Leading edge of the lymphocyte activation gene-3

Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab

Crystal structure of the human LAG-3–HLA-DR1–peptide complex

Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming

Lymphocyte-activation gene-3, an important immune checkpoint in cancer.

LAPTM5 promotes lysosomal degradation of intracellular CD3ζ but not of cell surface CD3ζ

CD4 ligand IL-16 inhibits the mixed lymphocyte reaction.